New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
08:11 EDTCVMCEL-SCI cleared to begin patient enrollment
CEL-SCI announced that Turkey's Ministry of Health had cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine. The news that Turkey has the 16th country to participate in the world's largest Phase III head and neck cancer trial of the firm's Leukocyte Interleukin, Injection follows last week's news that Sri Lanka's Ministry of Health had also cleared the company to commence patient enrollment in Sri Lanka. Similar clearances to conduct the Phase III study in the UK and Austria were announced in previous weeks and though it has becoming increasingly clear that CEL-SCI's expansion of the trial is finally going as planned, the valuation and share prices have yet to see a real impact.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
10:00 EDTCVMCEL-SCI says enrolled 29 patients in Phase 3 Multikine trial in January
CEL-SCI Corporation announced that during the month of January it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine in patients with advanced primary head and neck cancer. Total patient enrollment for the trial is now 697 as of January 31, 2016 in the Phase 3 study in head and neck cancer. The current study goal is to enroll 880 patients through approximately 100 clinical centers in over 20 countries. The Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care vs. subjects who are treated with SOC only.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use